With Tecfidera, Biogen Idec Delivers Best MS Product Launch Yet
This article was originally published in The Pink Sheet Daily
Biogen Idec blew past Wall Street estimates in its first quarter of revenue for its new, oral multiple sclerosis drug. But the biotech attributed much of the unexpected upside to quick conversions from another of its MS products, Tysabri.
You may also be interested in...
A new high-throughput assay developed at the University of California, San Francisco has already identified a generic over-the-counter drug that promotes remyelination. A clinical trial is soon to follow, only the second for myelin repair in multiple sclerosis.
The company expects dimethyl fumarate’s strong efficacy and favorable safety and tolerability profile to be an advantage against other oral multiple sclerosis drugs.
FDA approved the oral multiple sclerosis drug March 27 to treat patients with relapsing forms of the disease. Labeling includes data from one trial that showed patients on Tecfidera experienced disability progression less often.